Mr. Wolfgang Probst reports

BIONXT SOLUTIONS ANNOUNCES DEBENTURE UNIT FINANCING

Bionxt Solutions Inc. has arranged a non-brokered private placement of debenture units, with each unit consisting of 50 cents in principal amount of debenture bearing interest at a rate of 8.0 per cent per annum for a period of two years following the closing date, convertible into a common share in the capital of the company and one common share purchase warrant exercisable at 60 cents for a period of two years, for gross aggregate proceeds of up to $2.5-million. At the election of the company, the interest payable on the principal amount of the debentures may be paid through the issuance of common shares at a price of 50 cents per common share. The principal amount of the debentures is convertible at the option of the holder at any time prior to the maturity date.

The company anticipates issuing up to 400,000 compensation warrants, each exercisable into one common share in the capital of the company at 50 cents per finder's warrant, to eligible finders who introduce subscribers for the offering to the company, in addition to paying finders' fees in cash of up to 8 per cent of the subscriptions so introduced.

All securities issued in connection with the offering, including the finders' warrants, will be subject to a hold period of four months and one day from the date of issuance. Completion of the offering is subject to a number of conditions, including, but not limited to, receipt of any regulatory approvals as necessary.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

We seek Safe Harbor.